adtralza
leo pharma a/s - tralokinumab - dermatitis, atopic - drugi dermatološki preparati - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriaza - imunosupresivi - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
omvoh
eli lilly nederland b.v. - mirikizumab - kolitis, ulcerativni - imunosupresivi - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atopic - drugi dermatološki preparati - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.